The Supreme Court's decision on mifepristone could redefine FDA regulatory authority over abortion medications. This impacts tech professionals developing health apps and services related to reproductive health, as it may alter how digital health solutions are regulated and accessed. Watch for rulings that could set precedents for state versus federal control over pharmaceutical regulations.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



